Tag:
Zytiga
Latest Headlines
Latest Headlines
J&J's Zytiga may be useful in early prostate cancer, too
A new study suggests Zytiga may be effective in early-stage disease. The small trial--it involved only 58 patients with localized, high-risk cancer--found that Zytiga wiped out or nearly wiped out tumors in one-third of them.
ASCO data to shine new light on Pfizer, Roche, J&J drugs
Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.
Cancer drug experts brace for ASCO abstract dump tonight
ASCO is releasing a mountain of data on cancer studies, and some of the biggest names in the business will be angling for star billing on some closely watched therapies.
New discount persuades NICE to bless J&J's Zytiga
Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.
Tokai unveils promising Phase I data for 'triple whammy' prostate cancer contender
Cambridge, MA-based Tokai Pharmaceuticals presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer.
UPDATED: Dendreon's Provenge faces new questions
A new article questions the effectiveness of Dendreon's prostate cancer drug Provenge.
New Zytiga use could double sales potential
Analysts are rejigging their sales estimates for Johnson & Johnson's prostate cancer pill Zytiga , on the promise that it could target a much larger set of patients.
Zytiga data presents new threat to Provenge
Johnson & Johnson's ( $JNJ ) prostate cancer pill Zytiga has shown it's effective in patients who haven't yet received chemotherapy.
J&J wows analysts with early success of Zytiga PhIII for prostate cancer
The news just keeps getting better for Johnson & Johnson's new prostate cancer drug Zytiga (abiraterone).
NICE rejects J&J's Zytiga as too expensive
The U.K.'s cost-effectiveness gatekeepers want to shut out Johnson & Johnson's ( $JNJ ) new prostate cancer pill. The National Institute for Health and Clinical Excellence issued draft...
